Hepatorenal syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Hepatorenal syndrome}}
{{Hepatorenal syndrome}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}}{{SKA}}


==Overview==
==Overview==

Revision as of 15:32, 5 December 2017

Hepatorenal syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hepatorenal syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatorenal syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatorenal syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatorenal syndrome epidemiology and demographics

CDC on Hepatorenal syndrome epidemiology and demographics

Hepatorenal syndrome epidemiology and demographics in the news

Blogs on Hepatorenal syndrome epidemiology and demographics

Directions to Hospitals Treating Hepatorenal syndrome

Risk calculators and risk factors for Hepatorenal syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sunny Kumar MD [2]

Overview

Epidemiology and Demographics

It is estimated that 39% of patients with cirrhosis and ascites will develop hepatorenal syndrome within five years of the onset of their disease. The prognosis of these patients is grim with untreated patients having an extremely short survival, and with the severity of liver disease (as evidenced by the MELD score) now believed to determine outcome.[1] Some patients without cirrhosis develop hepatorenal syndrome, with an incidence of about 20% seen in one study of ill patients with alcoholic hepatitis.[2]

References

  1. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, Rodes J, Gines P. MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology 2005 Jun;41(6):1282-9. PMID 15834937
  2. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000 Dec;119(6):1637-48. PMID 11113085.

Template:WH Template:WS